Morgan Stanley lowered the target price for HEC CJ Pharma (01558) to HKD12.6 from HKD13.8 and maintained the "overweight" rating.
The research house said in light of weak flu incidence data in 4Q2024, it lowers 2024-2030 earnings estimates by 9-11% on lower antiviral sales.
27/12/2024 16:11
{I-bank focus}Morgan lowers HEC CJ Pharma (01558) to HKD12.6
Previous︰30/12/2024 15:22 {I-bank focus}Jefferies raises Yadea (01585) to HKD16
Next︰24/12/2024 15:21 {I-bank focus}Morgan lowers Sh Pharma (02607) to HKD17
02/01/2025 15:45 {I-bank focus}CCB keeps ENN Energy (02688) at HKD58
31/12/2024 16:06 {I-bank focus}Citi lowers Xinyi Solar (00968) to HKD3.1
31/12/2024 15:23 {I-bank focus}Citi lowers Yadea (01585) to HKD15.2
31/12/2024 14:40 {I-bank focus}Morgan raises U-Presid China (00220) to HKD6.1
24/12/2024 14:34 {I-bank focus}Morgan lowers Baiyunshan Ph (00874) to HKD21.4
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
